Centene Corporation (CNC) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Centene Corporation (CNC) surged +2.34% to $68.62 as options desks priced 56% call premium vs. 44% put protection around the $67 max-pain magnet. Solid 8% profit margin (-31% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Health coverage company Centene (NYSE:CNC) announced better-than-expected revenue in Q3 2026, with sales up 1.9% year on year to $50.65 billion. The company’s full-year revenue guidance of $198.5 billion at the midpoint
Wells Fargo analyst Stephen Baxter maintains Centene (NYSE:CNC) with a Equal-Weight and raises the price target from $69 to $75.
Centene delivered better-than-expected results in Q3 2026, buoyed by strength in its Medicare and Marketplace businesses. Management highlighted that favorable medical cost trends in Medicare Advantage and disciplined co
Lam Research, Lockheed Martin and Equinor headline today's analyst reports, with AI-driven demand, defense contracts and energy growth shaping their investment outlooks.
Oscar Health is broadening its growth beyond ACA insurance through Lucie and CHOICE, adding fee-based opportunities as its shares rise 116% year to date.
JP Morgan analyst John Stansel maintains Centene (NYSE:CNC) with a Neutral and raises the price target from $67 to $75.
Centene reported Q3 2026 revenue of US$50.65b with a GAAP net loss of US$71m, while adjusted EPS of US$0.58 exceeded market expectations and supported higher full year earnings and revenue guidance. The insurer paired st
Centene earnings beat and outlook reset Centene (CNC) just delivered third quarter earnings that topped analyst expectations, with Medicare results standing out and management raising both revenue and earnings guidance f
CNC raises its 2026 earnings outlook after Q3 results beat estimates, as Medicare recovery accelerates despite Medicaid enrollment and margin risks.
UBS analyst A.J. Rice maintains Centene (NYSE:CNC) with a Neutral and raises the price target from $70 to $78.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CNC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CNC. Explore sector supply chains on /butterfly.
Why CNC Stock surged +2.34% Today — RQD Quant Desk Flash. Solid 8% profit margin (-31% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.